Business
MEDITE Cancer Diagnostics to Launch SureCyte(TM) C1 Stain Globally at the 29th European Congress of Pathology
MEDITE Cancer Diagnostics to Launch SureCyte(TM) C1 Stain Globally at the 29th European Congress of Pathology.
About this update from Medite Cancer Diagnostics Inc
[{"type":"text","content":"\n \n \n MEDITE Cancer Diagnostics to Launch SureCyte(TM) C1 Stain Globally at the 29th European Congress of Pathology\n \n \nMEDITE Cancer Diagnostics to Launch SureCyte(TM) C1 Stain Globally at the 29th European Congress of Pathology\n\nRevolutionary product provides clinicians with accelerated, efficient staining process with enhanced digital imaging capabilities\n\n \n ORLANDO, FL--(Marketwired - Jul 27, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announced today that it will launch its SureCyte™ C1 fluorogenic instant staining product globally at the 29th Annual European Congress of Pathology in Amsterdam, Netherlands from September 2-5, 2017. \n MEDITE will initially concentrate its launch efforts in the U.S., European Union and China, leveraging existing commercial infrastructure already in place. The launch will be led by more than 20 distributors. MEDITE expects to begin generating revenues from C1 and related SureCyte instrument sales in the fourth quarter of 2017, and anticipates quarter-over-quarter revenue growth as the rollout expands. \n SureCyte offers lab efficiencies that enable improved patient care through a novel and innovative, self-mounting C1 stain with enhanced imaging when combined with a fluorescent microscope, assisting cytologists to visualize and quantify cellular structure to help determine whether the cells are normal, dysplastic or cancerous. This method has produced identical detection results to standard stains in cervical specimens in third party validation studies, and the fluorescent properties of the SureCyte stain produce digital images that MEDITE expects will advance the market transition to digital pathology and ultimately tele-pathology. \n The SureCyte C1 stain produces staining results within seconds, compared to the process associated with standard staining that typically takes 30 minutes or more, and a superior specificity and sensitivity profile positions the C1 stain as a direct replacement for the Pap and H&E stains used in most cytological and histological tests. SureCyte is the first of several planned product offerings under the SureCyte brand. \n \"Th...